Skip to main content
Erschienen in: Osteoporosis International 9/2014

01.09.2014 | Original Article

Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection

verfasst von: T. Porcelli, D. Gotti, A. Cristiano, F. Maffezzoni, G. Mazziotti, E. Focà, F. Castelli, A. Giustina, E. Quiros-Roldan

Erschienen in: Osteoporosis International | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

Summary

This study investigated the bone of HIV patients both in terms of quantity and quality. It was found that HIV-infected patients did fracture independently of the degree of bone demineralization as in other forms of secondary osteoporosis.

Introduction

We aimed to determine the prevalence of vertebral fractures (VFs) in HIV patients who were screened by bone mineral density (BMD) and to explore possible factors associated with VFs.

Methods

This is a cross-sectional study that included HIV-infected patients recruited in the Clinic of Infectious and Tropical Diseases and that underwent BMD measurement by dual-energy X-ray absorptiometry (DXA) at the lumbar spine and hip (Lunar Prodigy, GE Healthcare). For the assessment of VFs, anteroposterior and lateral X-ray examinations of the thoracic and lumbar spines were performed and were centrally digitized. Logistic regression models were used in the statistical analysis of factors associated with VFs.

Results

One hundred thirty-one consecutive patients with HIV infection (93 M, 38 F, median age 51 years; range, 36-75) underwent BMD measurement: 25.2 % of patients showed normal BMD, while 45 % were osteopenic and 29.7 % osteoporotic. Prevalence of low BMD (osteopenia and osteoporosis) was higher in females as compared to males (90 vs 69 %) with no significant correlation with age and body mass index. VFs occurred more frequently in patients with low BMD as compared to patients with normal BMD (88.5 vs. 11.4 %; p < 0.001) without any significant difference between osteopenia and osteoporosis (43 vs. 46 %; p = 0.073). VFs were significantly associated with older age and previous AIDS events.

Conclusions

These results suggest a BMD <−1 threshold to identify patients at risk of skeletal fragility and, therefore, good candidates for morphometric evaluation of spine X-ray in line with other forms of secondary osteoporosis with impaired bone quality.
Literatur
1.
Zurück zum Zitat Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, Klein RS (2007) Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 21:617–623PubMedCentralPubMedCrossRef Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, Klein RS (2007) Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 21:617–623PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Amiel C, Ostertag A, Slama L, Baudoin C, N’Guyen T, Lajeunie E et al (2004) BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 19:402–409PubMedCrossRef Amiel C, Ostertag A, Slama L, Baudoin C, N’Guyen T, Lajeunie E et al (2004) BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 19:402–409PubMedCrossRef
3.
Zurück zum Zitat Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, del Rio L et al (2010) High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 24:2827–2833PubMedCrossRef Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, del Rio L et al (2010) High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 24:2827–2833PubMedCrossRef
4.
Zurück zum Zitat Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J (2003) Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 17:1917–1923PubMedCrossRef Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J (2003) Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 17:1917–1923PubMedCrossRef
5.
Zurück zum Zitat Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N et al (2008) Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 22:395–402PubMedCrossRef Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N et al (2008) Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 22:395–402PubMedCrossRef
6.
Zurück zum Zitat Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL et al (2000) Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 14:F63–F67PubMedCentralPubMedCrossRef Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL et al (2000) Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 14:F63–F67PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Moore AL, Vashisht A, Sabin CA, Mocroft A, Madge S, Phillips AN et al (2001) Reduced bone mineral density in HIV-positive individuals. AIDS 15:1731–1733PubMedCrossRef Moore AL, Vashisht A, Sabin CA, Mocroft A, Madge S, Phillips AN et al (2001) Reduced bone mineral density in HIV-positive individuals. AIDS 15:1731–1733PubMedCrossRef
8.
Zurück zum Zitat Knobel H, Guelar A, Vallecillo G, Nogués X, Díez A (2001) Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS 15:807–808PubMedCrossRef Knobel H, Guelar A, Vallecillo G, Nogués X, Díez A (2001) Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS 15:807–808PubMedCrossRef
9.
Zurück zum Zitat Fausto A, Bongiovanni M, Cicconi P, Menicagli L, Ligabò EV, Melzi S et al (2006) Potential predictive factors of osteoporosis in HIV-positive subjects. Bone 38:893–897PubMedCrossRef Fausto A, Bongiovanni M, Cicconi P, Menicagli L, Ligabò EV, Melzi S et al (2006) Potential predictive factors of osteoporosis in HIV-positive subjects. Bone 38:893–897PubMedCrossRef
10.
Zurück zum Zitat Brown TT, Qaqish RB (2006) Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20:2165–2174PubMedCrossRef Brown TT, Qaqish RB (2006) Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20:2165–2174PubMedCrossRef
11.
Zurück zum Zitat Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB et al (2006) Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy. Clin Endocrinol 65:191–197CrossRef Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB et al (2006) Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy. Clin Endocrinol 65:191–197CrossRef
12.
Zurück zum Zitat Jacobson DL, Spiegelman D, Knox TK, Wilson IB (2008) Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr 49:298–308PubMedCentralPubMedCrossRef Jacobson DL, Spiegelman D, Knox TK, Wilson IB (2008) Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr 49:298–308PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, Gulanski B et al (2011) Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One 6:e17217PubMedCentralPubMedCrossRef Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, Gulanski B et al (2011) Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One 6:e17217PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Briot K, Kolta S, Flandre P, Boue F, Van Ngo P, Cohen-Codar I et al (2011) Prospective one-year bone loss in treatment-naive HIVR men and women on single or multiple drug HIV therapies. Bone 48:1133–1139PubMedCrossRef Briot K, Kolta S, Flandre P, Boue F, Van Ngo P, Cohen-Codar I et al (2011) Prospective one-year bone loss in treatment-naive HIVR men and women on single or multiple drug HIV therapies. Bone 48:1133–1139PubMedCrossRef
15.
Zurück zum Zitat Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL et al (2009) Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 23:817–824PubMedCrossRef Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL et al (2009) Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 23:817–824PubMedCrossRef
16.
Zurück zum Zitat Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD et al (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292:191–201PubMedCrossRef Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD et al (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292:191–201PubMedCrossRef
17.
Zurück zum Zitat Rivas P, Gorgolas M, Garcia-Delgado R, Diaz-Curie M, Goyenechea A, Fernandez-Guerrero M (2008) Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir. HIV Med 9:89–95PubMedCrossRef Rivas P, Gorgolas M, Garcia-Delgado R, Diaz-Curie M, Goyenechea A, Fernandez-Guerrero M (2008) Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir. HIV Med 9:89–95PubMedCrossRef
18.
Zurück zum Zitat Van Vonderen MG, Lips P, van Agtmael MA, Hassink EA, Brinkman K, Geerlings SE et al (2009) First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 23:1367–1376PubMedCrossRef Van Vonderen MG, Lips P, van Agtmael MA, Hassink EA, Brinkman K, Geerlings SE et al (2009) First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 23:1367–1376PubMedCrossRef
19.
Zurück zum Zitat McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P et al (2011) Bone mineral density and fractures in antiretroviral-naïve persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224 s, a substudy of ACTG A5202. J Infect Dis 203:1791–1801PubMedCentralPubMedCrossRef McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P et al (2011) Bone mineral density and fractures in antiretroviral-naïve persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224 s, a substudy of ACTG A5202. J Infect Dis 203:1791–1801PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB et al (2007) Bone mineral density remains stable in HAART treated HIV-infected men over 2 years. Clin Endocrinol 67:270–275CrossRef Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB et al (2007) Bone mineral density remains stable in HAART treated HIV-infected men over 2 years. Clin Endocrinol 67:270–275CrossRef
21.
Zurück zum Zitat Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D et al (2003) Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 36:482–490PubMedCrossRef Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D et al (2003) Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 36:482–490PubMedCrossRef
22.
Zurück zum Zitat Nolan D, Upton R, McKinnon E, John M, James I, Adler B et al (2001) Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 15:1275–1280PubMedCrossRef Nolan D, Upton R, McKinnon E, John M, James I, Adler B et al (2001) Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 15:1275–1280PubMedCrossRef
23.
Zurück zum Zitat Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N (2008) A reference standard for the description of osteoporosis. Bone 42:467–475PubMedCrossRef Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N (2008) A reference standard for the description of osteoporosis. Bone 42:467–475PubMedCrossRef
24.
Zurück zum Zitat Hans DB, Shepherd JA, Schwartz EN, Reid DM, Blake GM, Fordham JN et al (2008) Peripheral dual-energy X-ray absorptiometry in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom 11:188–206PubMedCrossRef Hans DB, Shepherd JA, Schwartz EN, Reid DM, Blake GM, Fordham JN et al (2008) Peripheral dual-energy X-ray absorptiometry in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom 11:188–206PubMedCrossRef
25.
Zurück zum Zitat Griffith JF, Genant HK (2012) New advances in imaging osteoporosis and its complications. Endocrine 42:39–51PubMedCrossRef Griffith JF, Genant HK (2012) New advances in imaging osteoporosis and its complications. Endocrine 42:39–51PubMedCrossRef
26.
Zurück zum Zitat McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS et al (2010) Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 51:937–946PubMedCentralPubMedCrossRef McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS et al (2010) Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 51:937–946PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Walker Harris V, Brown TT (2012) Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies. J Infect Dis 205:S391–S398PubMedCentralPubMedCrossRef Walker Harris V, Brown TT (2012) Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies. J Infect Dis 205:S391–S398PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat Torti C, Mazziotti G, Soldini PA, Focà E, Maroldi R, Gotti D et al (2012) High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine 41:512–517PubMedCrossRef Torti C, Mazziotti G, Soldini PA, Focà E, Maroldi R, Gotti D et al (2012) High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine 41:512–517PubMedCrossRef
29.
Zurück zum Zitat Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767PubMedCrossRef Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767PubMedCrossRef
31.
Zurück zum Zitat Pepe J, Isidori AM, Falciano M, Iaiani G, Salotti A, Diacinti D et al (2012) The combination of FRAX and Ageing Male Symptoms scale better identifies treated HIV males at risk for major fracture. Clin Endocrinol 77:672–678CrossRef Pepe J, Isidori AM, Falciano M, Iaiani G, Salotti A, Diacinti D et al (2012) The combination of FRAX and Ageing Male Symptoms scale better identifies treated HIV males at risk for major fracture. Clin Endocrinol 77:672–678CrossRef
32.
Zurück zum Zitat Mazziotti G, Bilezikian J, Canalis E, Cocchi D, Giustina A (2012) New understanding and treatments for osteoporosis. Endocrine 41:58–69PubMedCrossRef Mazziotti G, Bilezikian J, Canalis E, Cocchi D, Giustina A (2012) New understanding and treatments for osteoporosis. Endocrine 41:58–69PubMedCrossRef
33.
Zurück zum Zitat Oleksik A, Ott SM, Vedi S, Bravenboer N, Compston J, Lips P (2000) Bone structure in patients with low bone mineral density with or without vertebral fractures. J Bone Miner Res 15:1368–1375PubMedCrossRef Oleksik A, Ott SM, Vedi S, Bravenboer N, Compston J, Lips P (2000) Bone structure in patients with low bone mineral density with or without vertebral fractures. J Bone Miner Res 15:1368–1375PubMedCrossRef
34.
Zurück zum Zitat Mazziotti G, Bianchi A, Bonadonna S et al (2008) Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab 93:4649–4655PubMedCrossRef Mazziotti G, Bianchi A, Bonadonna S et al (2008) Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab 93:4649–4655PubMedCrossRef
35.
Zurück zum Zitat Angeli A, Guglielmi G, Dovio A et al (2006) High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39:253–259PubMedCrossRef Angeli A, Guglielmi G, Dovio A et al (2006) High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39:253–259PubMedCrossRef
36.
Zurück zum Zitat Mazziotti G, Canalis E, Giustina A (2010) Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 123:877–884PubMedCrossRef Mazziotti G, Canalis E, Giustina A (2010) Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 123:877–884PubMedCrossRef
37.
Zurück zum Zitat Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319–1328PubMedCrossRef Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319–1328PubMedCrossRef
38.
Zurück zum Zitat Mazziotti G, Porcelli T, Bianchi A, Cimino V, Patelli I, Mejia C et al (2010) Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. Eur J Endocrinol 163:15–20PubMedCrossRef Mazziotti G, Porcelli T, Bianchi A, Cimino V, Patelli I, Mejia C et al (2010) Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. Eur J Endocrinol 163:15–20PubMedCrossRef
39.
Zurück zum Zitat Mazziotti G, Porcelli T, Mormando M, De Menis E, Bianchi A, Mejia C et al (2011) Vertebral fractures in males with prolactinoma. Endocrine 39:288–293PubMedCrossRef Mazziotti G, Porcelli T, Mormando M, De Menis E, Bianchi A, Mejia C et al (2011) Vertebral fractures in males with prolactinoma. Endocrine 39:288–293PubMedCrossRef
40.
Zurück zum Zitat Mazziotti G, Bianchi A, Porcelli T, Mormando M, Maffezzoni F, Cristiano A et al (2013) Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab 98:3402–3410PubMedCrossRef Mazziotti G, Bianchi A, Porcelli T, Mormando M, Maffezzoni F, Cristiano A et al (2013) Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab 98:3402–3410PubMedCrossRef
41.
Zurück zum Zitat American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44:1496–1503CrossRef American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44:1496–1503CrossRef
42.
Zurück zum Zitat Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, Curtis JR et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 62:1515–1526CrossRef Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, Curtis JR et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 62:1515–1526CrossRef
43.
Zurück zum Zitat Wanner DP, Tyndall A, Walker UA (2009) Tenofovir-induced osteomalacia. Clin Exp Rheumatol 27:1001–1003PubMed Wanner DP, Tyndall A, Walker UA (2009) Tenofovir-induced osteomalacia. Clin Exp Rheumatol 27:1001–1003PubMed
44.
Zurück zum Zitat Grant PM, Kitch D, McComsey GA, Dube MP, Haubrich R, Huang J et al (2013) Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis 57:1483–1488PubMedCrossRef Grant PM, Kitch D, McComsey GA, Dube MP, Haubrich R, Huang J et al (2013) Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis 57:1483–1488PubMedCrossRef
45.
Zurück zum Zitat Brown TT (2013) HIV: an under-recognized secondary cause of osteoporosis? J Bone Miner Res 28:1256–1258PubMedCrossRef Brown TT (2013) HIV: an under-recognized secondary cause of osteoporosis? J Bone Miner Res 28:1256–1258PubMedCrossRef
46.
Zurück zum Zitat Maffezzoni F, Porcelli T, Karamouzis I et al (2014) Osteoporosis in human immunodeficiency virus patients—an emerging clinical concern. Eur Endocrinol 10:79–83 Maffezzoni F, Porcelli T, Karamouzis I et al (2014) Osteoporosis in human immunodeficiency virus patients—an emerging clinical concern. Eur Endocrinol 10:79–83
Metadaten
Titel
Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection
verfasst von
T. Porcelli
D. Gotti
A. Cristiano
F. Maffezzoni
G. Mazziotti
E. Focà
F. Castelli
A. Giustina
E. Quiros-Roldan
Publikationsdatum
01.09.2014
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 9/2014
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-014-2760-z

Weitere Artikel der Ausgabe 9/2014

Osteoporosis International 9/2014 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.